Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of omission of dexamethasone in premedication during paclitaxel treatment
2023-507481-43-00Phase 4Authorised
- Sponsor
- Erasmus MC
- Start
- Feb 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dexamethasone in Nonhematologic neoplasms (2 arms), sponsored by Erasmus MC. Primary endpoint: Clinically relevant hypersensitivity reactions (grade ≥3) during paclitaxel infusion. Planned start Feb 2024; status: authorised.
02
Drugs
dexamethasone
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2023-507481-43-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507481-43-00.